Imfinzi (durvalumab) - AstraZeneca
Andewei (benmelstobart) - Apollomics, Sino Biopharm
tiragolumab (RG6058) - Roche
Imjudo (tremelimumab-actl) - AstraZeneca
Yervoy (ipilimumab) - BMS
AiRuiLi (adebrelimab) - Jiangsu Hengrui Pharma
Tecentriq (atezolizumab) - Roche
Shan Ke Yu (socazolimab) - Lee's Pharm
Hetronifly (serplulimab) - Shanghai Henlius Biotech
etoposide IV - Generic mfg.
Keytruda (pembrolizumab) - Merck (MSD)
Focus V (anlotinib) - Advenchen
Tevimbra (tislelizumab-jsgr) - BeOne Medicines
Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology
http://www.ncbi.nlm.nih.gov/pubmed/42578486
 
Erika Ota; Hideki Sugita; Hisashi Noma; Masayuki Maeda; Miki Takenaka Sato; Noyuri Yamaji; Shunsuke Toyoda; Takenori Ichimura; Takeshi Hasegawa; Tomiko Sunaga
 
Aug 12, 2026
 
Prev Next